Summary
Global Markets Direct’s, ‘Urinary Incontinence - Pipeline Review, H2 2016’, provides an overview of the Urinary Incontinence pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence
- The report reviews pipeline therapeutics for Urinary Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Urinary Incontinence therapeutics and enlists all their major and minor projects
- The report assesses Urinary Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Urinary Incontinence
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Astellas Pharma Inc.
Celogos
Cook MyoSite Incorporated
FemmePharma Global Healthcare, Inc.
GTx, Inc.
Innovacell Biotechnologie AG
Ipsen S.A.
Outpost Medicine Limited
Taiho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
TheraVida, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Urinary Incontinence Overview 8
Therapeutics Development 9
Pipeline Products for Urinary Incontinence - Overview 9
Pipeline Products for Urinary Incontinence - Comparative Analysis 10
Urinary Incontinence - Therapeutics under Development by Companies 11
Urinary Incontinence - Therapeutics under Investigation by Universities/Institutes 12
Urinary Incontinence - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Urinary Incontinence - Products under Development by Companies 16
Urinary Incontinence - Products under Investigation by Universities/Institutes 17
Urinary Incontinence - Companies Involved in Therapeutics Development 18
Astellas Pharma Inc. 18
Celogos 19
Cook MyoSite Incorporated 20
FemmePharma Global Healthcare, Inc. 21
GTx, Inc. 22
Innovacell Biotechnologie AG 23
Ipsen S.A. 24
Outpost Medicine Limited 25
Taiho Pharmaceutical Co., Ltd. 26
Takeda Pharmaceutical Company Limited 27
TheraVida, Inc. 28
Urinary Incontinence - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
(mirabegron + solifenacin succinate) - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
abobotulinumtoxin A - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ASP-2205 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Cell Therapy for Urinary Incontinence - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
enobosarm - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Gtx-027 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
ICES-13 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
OP-233 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
oxybutynin chloride - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Prof-003 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
RCD-1 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
TAS-303 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
THVD-201 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
THVD-202 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Urinary Incontinence - Dormant Projects 66
Urinary Incontinence - Discontinued Products 69
Urinary Incontinence - Product Development Milestones 71
Featured News & Press Releases 71
Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting 71
Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting 71
Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence 72
Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence 72
May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 73
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 74
Jan 03, 2013: TheraVida Announces Positive Top-line Phase II Results For Tolenix In Patients With Overactive Bladder And Urge Urinary Incontinence 74
Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference 75
Dec 05, 2011: Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients 75
Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency 76
Aug 30, 2011: Innovacell passes a further milestone 76
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 77
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201 78
Feb 22, 2011: Innovacell makes further progress on product development 78
Jun 28, 2010: Astellas and Teva reached a Settlement Agreement on VESIcare Patent Case 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81
List of Tables
Number of Products under Development for Urinary Incontinence, H2 2016 9
Number of Products under Development for Urinary Incontinence - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Urinary Incontinence - Pipeline by Astellas Pharma Inc., H2 2016 18
Urinary Incontinence - Pipeline by Celogos, H2 2016 19
Urinary Incontinence - Pipeline by Cook MyoSite Incorporated, H2 2016 20
Urinary Incontinence - Pipeline by FemmePharma Global Healthcare, Inc., H2 2016 21
Urinary Incontinence - Pipeline by GTx, Inc., H2 2016 22
Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2016 23
Urinary Incontinence - Pipeline by Ipsen S.A., H2 2016 24
Urinary Incontinence - Pipeline by Outpost Medicine Limited, H2 2016 25
Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 26
Urinary Incontinence - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 27
Urinary Incontinence - Pipeline by TheraVida, Inc., H2 2016 28
Assessment by Monotherapy Products, H2 2016 29
Assessment by Combination Products, H2 2016 30
Number of Products by Stage and Target, H2 2016 32
Number of Products by Stage and Mechanism of Action, H2 2016 34
Number of Products by Stage and Route of Administration, H2 2016 36
Number of Products by Stage and Molecule Type, H2 2016 38
Urinary Incontinence - Dormant Projects, H2 2016 66
Urinary Incontinence - Dormant Projects (Contd..1), H2 2016 67
Urinary Incontinence - Dormant Projects (Contd..2), H2 2016 68
Urinary Incontinence - Discontinued Products, H2 2016 69
Urinary Incontinence - Discontinued Products (Contd..1), H2 2016 70
List of Figures
Number of Products under Development for Urinary Incontinence, H2 2016 9
Number of Products under Development for Urinary Incontinence - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 14
Assessment by Monotherapy Products, H2 2016 29
Number of Products by Targets, H2 2016 31
Number of Products by Stage and Targets, H2 2016 31
Number of Products by Mechanism of Actions, H2 2016 33
Number of Products by Stage and Mechanism of Actions, H2 2016 33
Number of Products by Routes of Administration, H2 2016 35
Number of Products by Stage and Routes of Administration, H2 2016 35
Number of Products by Molecule Types, H2 2016 37
Number of Products by Stage and Top 10 Molecule Types, H2 2016 37
